Marksans Pharma said that the UK MHRA has granted market authorisation to the company's wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml oral solution.
The drug maker said that the therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK.
Mumbai-based Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets.
The drug maker consolidated net profit rose 29.9% to Rs 60.12 crore on a 25.3% increase in revenue from operations to Rs 452.56 crore in Q2 FY23 over Q2 FY22.
The scrip fell 1.41% to currently trade at Rs 66.20 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
